Therapeutic Area Focus Could Pay Off In Biomarker Discovery, Bristol VP Says
Having an R&D focus on targeted therapeutic areas could be beneficial in terms of developing biomarkers, according to a Bristol-Myers Squibb exec
You may also be interested in...
Bristol-Myers Squibb believes it has the "critical mass" in R&D and sales to continue as a stand-alone company, CEO Peter Dolan said Jan. 29 during the company's year end earnings call
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials